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Abstract
Purpose of review—The erythroid progenitors BFU-E (burst-forming unit-erythroid) and CFU-
E (colony-forming unit-erythroid) have a critical role in erythropoiesis. They represent a 
heterogeneous and poorly characterized population of cells with modifiable self-renewal, 
proliferation and differentiation capabilities. This review focuses on the current state of erythroid 
progenitor biology with regard to immunophenotypic identification and regulatory programs; in 
addition, we will discuss the therapeutic implications of using these erythroid progenitors as 
pharmacologic targets.
Recent findings—Erythroid progenitors are classically defined by the appearance of 
morphologically defined colonies in semisolid cultures. However, these prior systems preclude a 
more thorough understanding of the composite nature of progenitor populations. Recent studies 
employing novel flow cytometric and cell-based assays have helped to redefine hematopoiesis, and 
suggest that erythroid progenitors may arise from different levels of the hematopoietic tree. 
Moreover, the identification of cell surface marker patterns in human BFU-E and CFU-E enhance 
our ability to perform downstream functional and molecular analyses at the population and single 
cell level. Advances in these techniques have already revealed novel subpopulations with increased 
self-renewing capacity, roles for erythroid progenitors in globin gene expression, and insights into 
pharmacologic mechanisms of glucocorticoids and pomalidomide.
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Summary—Immunophenotypic and molecular characterization resolves the diversity of 
erythroid progenitors and may ultimately lead to the ability to target these progenitors to 
ameliorate diseases of dyserythropoiesis.
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Introduction
Although identified in the 1970s, few studies have focused exclusively on detailed cellular 
and molecular characterization of the erythroid progenitors, BFU-Es and CFU-Es, which are 
central to the generation of red blood cells during erythropoiesis. The development of new 
methodologies has enabled the isolation and molecular characterization of erythroid 
progenitors. This review focuses on recent advances made in erythropoiesis, including 
immunophenotyping, regulation of self-renewal and differentiation, and the pharmacological 
targeting of erythroid progenitors for the treatment of anemia.
Hematopoiesis revisited: implications for erythroid differentiation
The conventional hematopoietic hierarchy depicts multipotent long-term and short-term 
hematopoietic repopulating stem cells at the apex, which give rise to progressively more 
differentiated hematopoietic progenitors and terminal blood cell lineages. The first branch 
point after the multipotent progenitor (MPP) divides lymphoid and myelo-erythroid lineages 
at the common lymphoid progenitor (CLP) and common myeloid progenitor (CMP) (1). 
Two additional hematopoietic progenitors emerge from CMPs including the oligopotent 
granulocyte macrophage progenitor (GMP) and bipotent megakaryocyte-erythroid 
progenitor (MEP) (2). Further commitment of MEPs toward the erythroid lineage is marked 
by the formation of BFU-E, the first erythroid restricted progenitor (3). BFU-Es ultimately 
differentiate into the erythropoietin(EPO)-sensitive CFU-E, which then progress through a 
series of erythroblast stages, reticulocyte maturation and ultimately terminal red cell 
formation (4). Thus, in this classical model of hematopoiesis, erythropoiesis relies on the 
stepwise differentiation of increasingly erythroid restricted hematopoietic progenitors 
(Figure 1A).
Studies over the last decades in mice and more recently humans, have revised this model of 
hematopoiesis through the identification of alternative differentiation pathways and 
subpopulations within these previously defined progenitor stages. Hematopoietic progenitors 
may branch earlier than previously thought, as megakaryo-erythroid and myelo-lymphoid 
potential have been shown to diverge at a lymphoid-primed multipotent progenitor (LMPP); 
this route bypasses MPP and CMP (5, 6). Alternatively, myelo-erythroid output may 
predominantly rely on myeloid-restricted progenitors with long-term repopulating activity. 
These cells undertake a “myeloid bypass” whereby oligo- and bi-potent progenitors with 
self-renewing capacity at the single cell level give rise to erythroid, megakaryocyte and 
granulocyte-macrophage lineages (7). There is also growing evidence that the bipotent MEP 
contains multiple populations with varying lineage biases (8*, 9*).
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Furthermore, hematopoiesis appears to be developmental stage specific. Through the use of 
novel single cell lineage potential assays and single cell transcriptome analyses, Notta et al. 
recently demonstrated that the fetal hematopoietic tree consists of multi-, oligo- and uni-
potent progenitors, whereas adult hematopoiesis relies mostly on unipotent progenitors 
(Figure 1B–C). In addition, a higher amount of erythroid-megakaryocyte progenitors were 
shown to branch directly from the multipotent and oligopotent fractions during fetal 
hematopoiesis suggesting that the regulation of erythroid biased programs differ in fetal and 
adult hematopoietic progenitors (10**). It remains to be determined whether the fetal and 
adult erythroid progenitors derived from varying levels of the hematopoietic tree also differ 
at transcriptional and functional levels (i.e. higher self-renewal, differential globin gene 
expression). Future investigations should focus on these progenitors to identify whether all 
erythroid progenitors possess “memory” from their hematopoietic predecessors and whether 
this carries physiologic significance.
Isolation and characterization of megakaryocyte-erythroid and erythroid 
progenitors
Initial studies first identified the erythroid restricted progenitors, BFU-E and CFU-E, as well 
as early BFU-E with megakaryocyte potential by the morphology of hematopoietic colonies 
formed in semisolid media (11*). Later studies confirmed the existence of a discrete bipotent 
MEP using colony forming assays and a limited panel of cell surface markers by flow 
cytometry (12). Although crucial for our basic understanding of erythroid progenitor 
biology, these early studies were unable to discern the considerable variability among 
progenitor populations that advances in flow cytometry, genomic approaches (e.g. global and 
single cell RNA-seq) and novel in vitro culture systems have more recently highlighted.
An extensive discussion of the MEP is beyond the scope of this review; however, it should 
be noted that in contrast to murine hematopoiesis (13), a clear consensus for the cell surface 
markers that define human MEPs is lacking. As summarized in Table 1, MEPs have been 
characterized using a combination of cell surface markers including IL-3R, FLT3, MPL 
(assessed using BAH1 clone and other antibodies), CD36, CD41, CD71 and CD105 (8*, 9*, 
10**, 14**). Using a combination of approaches including functional, single cell 
transcriptomics and lineage potential assays, these studies reveal that the identification of 
MEP and their subpopulations appears highly dependent on gating strategy; this likely 
reflects their extensive heterogeneity.
To date, few gating strategies exist for erythroid progenitors, and therefore considerably less 
is known about their heterogeneity (Table 1). Murine studies identify fetal liver BFU-Es and 
CFU-Es as c-Kit+CD45+Ter119−CD71low and c-Kit+CD45−Ter119−CD71hi, respectively 
(15), while murine bone marrow CFU-Es are characterized as Lin−c-
Kit+Sca-1−IL-7Rα−IL3Rα−CD41−CD71+ cells (16). The immunophenotypic identity of 
human erythroid progenitors was less clear, until Li et al. first demonstrated that BFU-E 
reside in the IL-3R−GPA−CD34+CD36− fraction, and IL-3R−GPA−CD34−CD36+ denotes 
CFU-E. These populations give rise to characteristically pure colonies in methylcellulose 
and discrete gene expression signatures by RNAseq (17**). More recently, in the murine 
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system, Gao et al. used single cell RNAseq to demonstrate that the transient expression of 
Type-III Transforming Growth Factor-β Receptor (TβRIII) distinguished early (large cluster 
forming) BFU-E and late (small cluster forming) BFU-E in fetal livers (18*). Whether these 
TβRIII− cells represent a novel more immature BFU-E or a functional subpopulation of 
BFU-E requires further investigation.
Despite these pivotal studies, the utility of these markers may only apply to steady-state 
erythropoiesis. Indeed, stress erythroid progenitors express the cell surface markers 
CD34−CD133−c-Kit+Sca-1+ and CD34−CD133−c-Kit+ in mice and human-derived cells, 
respectively (19*). Thus, erythroid progenitors represent a heterogeneous population of 
cells, and moving forward, it will be critical to understand the regulatory mechanisms that 
underlie this diversity.
Regulation of erythroid progenitor self-renewal, proliferation and 
differentiation
Erythroid progenitors uniquely act as a critical interface between the hematopoietic stem cell 
and the more mature stages, dictating programs that eventually control the function of 
terminal erythroblasts. Indeed, terminal erythroblasts are largely pre-programmed, and as 
cells enter terminal erythroid differentiation they possess little or no capabilities for 
proliferation and self-renewal (20**). This programming confines erythroblasts to one 
division per stage with a single proerythroblast giving rise to 16 or 32 enucleate 
reticulocytes. Therefore, an active area of investigation lies in the identification and 
understanding of how these progenitors integrate soluble, cell-contact and cell-autonomous 
signals in order to control red cell mass and differentiation programs.
Cytokines and growth factors
Soluble factors that govern erythroid progenitor physiology come from diverse families of 
signaling molecules, and often work synergistically to amplify progenitor numbers. For 
example, stem cell factor (SCF), the ligand for c-kit receptor, cooperates with erythropoietin 
(EPO), TGF-α, insulin-like growth factor 1 (IGF-1) and IL-3 in regulating erythroid 
progenitor biology. Studies using erythroid cell lines and primary CFU-Es demonstrate that 
the synergy of SCF and EPO act at the receptor and downstream effector levels (21–24). 
Moreover, SCF and TGF-α increases growth and self-renewal of avian erythroid progenitors 
(25). Additional factors that synergize with SCF include IL-3 and IGF-1. IL-3 and SCF 
increase BFU-Es in liquid cultures (26), and SCF and IGF-1 enhance peripheral blood 
erythroid progenitors ex vivo (27).
IL-3 also functions independently of SCF at the BFU-E stage. IL-3 stimulates BFU-E 
proliferation (28), and may regulate self-renewal as evidenced by the emergence of sub-
colonies in methylcellulose (29). Further, IL-3 with activin A induces BFU-E mitogenesis 
and increased colony numbers (30).
TGF-β exerts a pro-differentiation role during early erythropoiesis. The expression of 
CD105 (endoglin) on human erythroid progenitors accelerates their differentiation in the 
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presence of TGF-β (8*), and TβRIII expression appears restricted to BFU-E subpopulations 
with diminished self-renewing capacity in vitro (18*).
Despite the cooperative nature of these signaling molecules, murine studies implicate EPO 
and SCF as the sole endogenous factors required for mammalian erythroid progenitors. 
SCF/c-kit mutant and EPO-R deficient mice both exhibit severe anemia with varying 
erythroid progenitor defects, whereas erythropoiesis remains unaffected in the absence of 
IL-3R (31–33). Activating mutations in the c-kit receptor prevent erythroblast maturation, 
and expand progenitors (34*). Further, EPO acts directly on CFU-Es to promote survival as 
opposed to proliferation (35). In the absence of EPO, CFU-Es undergo apoptosis through the 
FAS-FAS ligand pathway, and fail to progress into terminal erythroid differentiation (36, 
37).
Extracellular signals may also promote the expansion and differentiation of specialized 
erythroid progenitors during times of erythropoietic stress. Studies in mice and more 
recently in humans have shown that in addition to EPO and SCF, hypoxia, bone 
morphogenic protein 4 (BMP4), growth differentiation factor-15 (GDF-15) and hedgehog 
contribute to the expansion of BFU-Es during stress erythropoiesis. These progenitors also 
express higher levels of genes associated with self-renewal such as Pu.1 and GATA2 (19).
A largely unanswered question is how and in what context cytokines shape the 
transcriptional landscape and composition of erythroid progenitor subpopulations as well as 
the functional consequences of soluble factor signaling.
Cell intrinsic
Considerably less is known regarding how intrinsic factors such as transcriptional, post-
transcriptional and translational regulators control erythroid progenitor function. However, it 
is well appreciated that discrete gene subsets must be turned on and off in progenitors and 
terminal erythroblasts to facilitate the proper balance of self-renewal and differentiation. The 
reciprocal expression of the GATA family of transcription factors, GATA2 and GATA1, 
during erythropoiesis exemplifies this necessity (38). These studies indicate that the 
expression of self-renewal genes by sustained GATA2 expression could theoretically lead to 
increased levels of erythroid progenitors (39). Although GATA2 functions in multiple 
hematopoietic lineages, its overexpression leads to megakaryocyte differentiation (40, 41) 
suggesting that the careful dosage of transcription factors is needed for self-renewing pro-
erythroid transcriptional programs. A similar dose-dependent mechanism may underlie PU.
1-mediated BFU-E self-renewal. PU.1 is highly expressed in multi- and oligo-potent 
progenitors as well as in more committed myeloid and lymphoid cells, and is proposed to 
mediate BFU-E self-renewal at low levels (42). Fetal liver cells null for PU.1 show 
perturbations of erythroid progenitor numbers including attenuated proliferative capacity, 
accelerated differentiation and failure to respond to SCF and EPO (43). The exact molecular 
mechanisms remain elusive as PU.1 binding partners and gene targets have yet to be defined 
in primary erythroid progenitor populations.
In addition to transcriptional controls, RNA stability and accessibility to translational 
machinery could also determine erythroid progenitor self-renewal. The RNA binding protein 
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ZFP36L2, which is strongly induced following glucocorticoid receptor agonism in murine 
progenitors, promotes BFU-E self-renewal by negatively regulating gene transcripts 
associated with terminal erythroid differentiation and delaying the BFU-E to CFU-E 
transition (44). An additional, largely unstudied RNA binding protein in erythroid 
progenitors is LIN28B. LIN28B regulates the expression of the let7 family of microRNAs 
and HMGA2, which plays a critical role in fetal hematopoiesis (45**, 46*). Furthermore, 
fetal CFU-Es exhibit increased responsiveness to EPO, and therefore, the LIN28B-let7-
HMGA2 axis may possess an unappreciated function during fetal erythropoiesis (47). Since 
ectopic expression of LIN28B has already been shown to induce HbF in adult erythroid 
progenitors (48), investigation into whether this also affects erythroid progenitor self-
renewal should be explored.
The erythroblastic island
These critical niches for erythropoiesis are composed of a central macrophage surrounded 
by differentiating erythroid cells at all stages of maturation beginning with the CFU-E. 
Through still poorly elucidated mechanisms, it is hypothesized that BFU-E migrate towards 
these islands, and following differentiation to CFU-E, adhere to macrophages through a 
number of different molecules (49, 50**, 51*). Whether central macrophages promote CFU-
E self-renewal or merely increase proliferation of CFU-E/Pro-EB requires further 
investigation. However, in vitro and murine studies clearly demonstrate an essential function 
for erythroblastic islands during steady-state and stress erythropoiesis (52, 53).
Erythroid progenitors as a target for treating disordered erythropoiesis
As previously mentioned, erythroid progenitors are crucial for determining the overall red 
cell mass. It is therefore not surprising that erythroid defects such as the inherited bone 
marrow failure syndromes (e.g. Diamond Blackfan anemia [DBA]) demonstrate a paucity of 
erythroid progenitors, specifically CFU-Es (54*, 55). Although two major theories, (i) 
increased p53 levels or (ii) translational defect of GATA1, have been proposed as central to 
the pathophysiology of DBA, it is generally accepted that the apoptosis of the EPO-
responsive CFU-E causes the red cell failure associated with the disease (56–58). Thus, 
understanding why these progenitor cells are exquisitely sensitive to abnormal translational 
and how to pharmacologically target these progenitors remains a fundamental goal.
There is a limited number of pharmacologic agents that directly target erythroid progenitors. 
Since activin and BMP signaling stimulates BFU-E self-renewal, and TGF-β accelerates 
erythroid differentiation, therapeutic interventions aimed at the TGF-β superfamily may 
ameliorate certain cases of anemia. Indeed, inhibition of the TβRI kinase by Galunisertib 
augments the number of immature early-BFU-E (18*). The ligand trap activin receptor type 
IIA and IIB fusion proteins, RAP-011 and RAP-536 respectively, stimulate red cell 
production in normal and ineffective erythropoiesis; these molecules preclude activation of 
SMAD2/3 by growth differentiation factor-11 (GDF-11) (59, 60). Whether these compounds 
act at the level of the BFU-E and/or CFU-E in addition to their action on terminally 
differentiating erythroblasts is unclear.
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Glucocorticoids (e.g. prednisone and dexamethasone) are the current standard of care for 
DBA and other hematologic conditions including warm autoimmune hemolytic anemia. 
They are hypothesized to act at the level of the erythroid progenitors (61). However, the 
mechanism of action of glucorticoids in erythropoiesis remains unclear. Conflicting findings 
in murine and human systems have generated controversy regarding the exact progenitor 
stage at which glucocorticoids act (44, 62*, 63*). Furthermore, in vitro studies utilizing 
dexamethasone as an expansion agent prevent a stage-specific assessment of its function on 
erythroid progenitors (64). Together, glucocorticoids may exhibit species specificity with the 
targeted population being BFU-E and CFU-E in mice and humans, respectively. Indeed, data 
from others (61) and our unpublished data suggest that in humans, dexamethasone acts at the 
CFU-E stage (Figure 2A,B). Further experimentation using purified human erythroid 
progenitors is currently being explored to understand the molecular and stage-specific 
actions of glucocorticoids.
There is increasing evidence that the immunomodulatory drugs (IMiDs), pomalidomide and 
lenalidomide, target erythroid progenitors at the level of the BFU-E or during the transition 
of the BFU-E to CFU-E stage. Lenalidomide increases CFU-Es suggesting that these drugs 
could be used to stimulate red blood cell production (65). Alternatively, IMiDs also induce 
fetal hemoglobin (HbF) production in adult-derived CD34+ HSPCs, and pomalidomide 
appears to exert this effect at the level of the BFU-E (66**). A provocative implication from 
these studies is that globin gene regulatory programs reside in erythroid progenitors. Indeed, 
Papayonnopoulou and collaborators provide early evidence of this phenomenon, and imply 
that a minority of “pre-programmed” adult erythroid progenitors give rise to erythroblasts 
expressing HbF (67, 68). Therefore, the most effective pharmacologic agents might exploit 
the regulatory mechanisms in erythroid progenitors to either enrich this small population of 
“HbF programmed cells” or override γ-globin silencing in the majority of BFU-Es engaged 
with adult globin expression regulatory factors (Figure 2C).
Conclusion
The rapidly growing technological advances such as genomic, proteomic and cell biological 
characterization of single cells and advances in flow cytometry approaches are likely to add 
to our understanding of the role, regulation and differentiation potential of erythroid 
progenitors, and their contribution to red cell production. Ultimately, these findings will lead 
to the discovery of new therapies for the treatment of disorders of erythropoiesis.
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Keypoints
1. Recent advances reveal that erythroid progenitors are not a uniform 
population, but rather, composed of different subpopulations with variable 
levels of self-renewing capabilities.
2. The discovery of cell surface marker panels that resolve BFU-Es and CFU-Es 
populations enables the study of erythroid progenitor dynamics in vivo and in 
vitro.
3. An active area of investigation is how erythroid progenitors integrate soluble, 
cell intrinsic and microenvironment signals to regulate self-renewal, 
proliferation and differentiation.
4. BFU-Es and CFU-Es may represent appealing population of cells for 
pharmacologic stimulation of fetal hemoglobin and red blood cell mass.
5. Due to the molecular and cellular heterogeneity of erythroid progenitors, 
future studies should use single cell approaches whenever feasible.
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Figure 1. Erythroid lineage potential arises from different progenitor subsets according to 
revised hematopoietic hierarchy
(A) Classical view of hematopoiesis suggests that erythroid progenitors are derived from 
discrete multipotent progenitors populations that undergo a series of differentiation steps 
whereby these progenitor cells become increasingly erythroid restricted. (B–C) New insights 
reveal that hematopoiesis is specific of the developmental stage and progenitor populations 
are heterogeneous. A simplified view of these findings with an emphasis on erythroid 
differentiation is depicted. During fetal hematopoiesis (B), erythroid potential arises from 
multipotent, oligopotent and unipotent progenitors. Conversely, the adult erythroid lineage 
(C) is derived from multipotent stem and predominantly unipotent progenitors. Finally, and 
common to both, erythroid progenitors can arise from a bypass directly from the multipotent 
progenitor.
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Figure 2. Pomalidomide and glucocorticoids are hypothesized to act on different erythroid 
progenitor populations
(A) During steady-state erythropoiesis in the adult, the BFU-E population contains a small 
minority of HbF-producing cells (purple), and cells possess limited self-renewal. BFU-Es 
differentiate into CFU-Es followed by erythroid precursors and erythrocytes containing 
mainly adult hemoglobin (HbA). (B) Glucocorticoids appear to affect erythroid progenitors 
in a species-specific manner. In mice, glucocorticoids increase BFU-E self-renewal (green), 
whereas increased CFU-Es may result from glucocorticoid treatment in humans. The 
proportion of HbF-producing cells (purple) remains unchanged by glucocorticoid treatment. 
(C) Pomalidomide exerts its effect at BFU-E or on the BFU-E to CFU-E transition to induce 
HbF and increase BFU-E numbers through two potential mechanisms: (i) stimulate the 
expansion of pre-programmed HbF producing BFU-E (purple) or (ii) reprogram adult 
progenitors to prevent γ-globin repression (striped).
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